Vaccines have advantages over natural infections. For one, they can be designed to focus the immune system against specific antigens that elicit better responses.
There are about 2,000 drugs and vaccines (mostly the former) now in clinical trials. ACSH advisor Dr. Henry Miller argues that to get COVID-19 under control we will need therapeutics no matter how effective vaccines are. Here's why.
The University of Oxford, in collaboration with British pharmaceutical firm AstraZeneca, has produced a leading coronavirus vaccine candidate. However, the Phase 3 clinical trial was paused because one patient is thought to have developed a serious adverse reaction. What could it be?
New research from The Scripps Research Institute in San Diego found that protective IgG antibodies, one of five major classes of antibodies, may not be the most important ones when it comes to fighting off a flu infection. This insight may help make future flu vaccines and other treatments much more effective.